8,870 reports of this reaction
8.7% of all ESTROGENS, CONJUGATED reports
#2 most reported adverse reaction
BREAST CANCER FEMALE is the #2 most commonly reported adverse reaction for ESTROGENS, CONJUGATED, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 8,870 FDA adverse event reports linking ESTROGENS, CONJUGATED to BREAST CANCER FEMALE. This represents approximately 8.7% of all 102,186 adverse event reports for this drug.
Patients taking ESTROGENS, CONJUGATED who experience breast cancer female should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER FEMALE is moderately reported among ESTROGENS, CONJUGATED users, representing a notable but not dominant share of adverse events.
In addition to breast cancer female, the following adverse reactions have been reported for ESTROGENS, CONJUGATED:
The following drugs have also been linked to breast cancer female in FDA adverse event reports:
BREAST CANCER FEMALE has been reported as an adverse event in 8,870 FDA reports for ESTROGENS, CONJUGATED. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER FEMALE accounts for approximately 8.7% of all adverse event reports for ESTROGENS, CONJUGATED, making it one of the most commonly reported side effect.
If you experience breast cancer female while taking ESTROGENS, CONJUGATED, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.